Atorvastatin improves the BM EPCs of immune thrombocytopenia patients by down-regulating the p38 MAPK pathway and up-regulating the AKT pathway in number and function
Atorvastatin improves the BM EPCs of immune thrombocytopenia patients by down-regulating the p38 MAPK pathway and up-regulating the AKT pathway in number and function. and migration were significantly enhanced by…